Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 29.09.2025 1 Ann Oncol 3 Ann Surg Oncol 1 Ann Thorac Surg 3 Br J Cancer 1 Cancer 2 Cancer Res 1 Cancer Sci 3 Clin Lung Cancer 4 Eur J Cardiothorac Surg 1 Int J Radiat Oncol Biol Phys 1 J Immunol 5 Lung Cancer 1 Mol Carcinog 1 Oncogene 2 Oncol Rep 2 Oncologist 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Oncol

1. WILCOX JA, Jeng MY, Tischfield S, Sui JSY, et al
   Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases.
   Ann Oncol. 2025;36:1142-1153.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. ZHONG G, Chen Y, Lai H, He J, et al
   Beyond the Scalpel: EGFR Mutation Predicts Intraoperative Blood Loss and Transfusion Needs During Lung Cancer-derived Spinal Metastasis Surgery.
   Ann Surg Oncol. 2025 Sep 23. doi: 10.1245/s10434-025-18332.
   PubMed         Abstract available
   
   
3. MOTT NM, Meguid RA, Randhawa SK, David EA, et al
   Social Vulnerability is Associated with Significant Delays to Definitive Surgery for Stages IA to IIIA Non-small Cell Lung Cancer and Consequential Increased Rates of Pathologic Upstaging.
   Ann Surg Oncol. 2025 Sep 20. doi: 10.1245/s10434-025-18337.
   PubMed         Abstract available
   
   
4. LOMBARDO J, Florea IB, Toomey N, Khrizman P, et al
   The Landmark Series: Role of Curative Intent Treatment for Oligometastatic Disease of the Lung.
   Ann Surg Oncol. 2025;32:7845-7851.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

5. WAGEMAKER VIANA S, Van Haren RM
   Bridging the Gap in Lung Cancer Screening: Lessons from a Culturally Tailored Intervention with Lay Navigators.
   Ann Thorac Surg. 2025 Sep 19:S0003-4975(25)00886.
   PubMed        
   
   

   
   Br J Cancer

6. TAKEZAWA K, Okamoto I, Tsukioka S, Uchida J, et al
   Retraction Note: Identification of thymidylate synthase as a potential therapeutic target for lung cancer.
   Br J Cancer. 2025 Sep 19. doi: 10.1038/s41416-025-03211.
   PubMed        
   
   
7. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
   Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
   Br J Cancer. 2025;133:874-885.
   PubMed         Abstract available
   
   
8. SAKAI SA, Oyoshi H, Nakamura M, Taki T, et al
   Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy.
   Br J Cancer. 2025;133:795-808.
   PubMed         Abstract available
   
   

   
   Cancer

9. ISLAMI F, Wiese D, Schafer EJ, Sung H, et al
   Stage-specific cancer survival in Black and White persons by urbanicity of county of residence, United States, 2015-2021.
   Cancer. 2025;131:e70073.
   PubMed         Abstract available
   
   

   
   Cancer Res

10. GEBRU MT, Hoffman TE, Boudreau A, Vu N, et al
    Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1-Mutant Lung Cancer.
    Cancer Res. 2025 Sep 18. doi: 10.1158/0008-5472.CAN-24-4887.
    PubMed         Abstract available
    
    
11. PAN T, Zhu J, Wang X, Tang D, et al
    MEN1 Promotes Ferroptosis by Disrupting CD44 Alternative Splicing to Suppress Lung Cancer.
    Cancer Res. 2025 Sep 24. doi: 10.1158/0008-5472.CAN-25-0021.
    PubMed         Abstract available
    
    

    
    Cancer Sci

12. ZENKE Y, Shiraishi Y, Goto Y, Azuma K, et al
    Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.
    Cancer Sci. 2025 Sep 21. doi: 10.1111/cas.70188.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

13. MORINAGA D, Furuta M, Morita S, Miyauchi E, et al
    A Phase 2 Study of Osimertinib in Combination With Platinum-Pemetrexed in Patients With Uncommon Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer (NEJ067/OPAL2).
    Clin Lung Cancer. 2025 Aug 26:S1525-7304(25)00219.
    PubMed         Abstract available
    
    
14. BRAMBILLA M, Barbetta F, Nardo G, Agnelli L, et al
    Refining High-Risk EGFR-Mutant Lung Cancer Patients: The Role of Adjusted Variant Allele Frequency in First-Line Osimertinib Therapy.
    Clin Lung Cancer. 2025 Aug 31:S1525-7304(25)00221.
    PubMed         Abstract available
    
    
15. MUDD J, Zafar H, Mhango G, Slatore CG, et al
    Provider Bias in Decision Making About Treatment of Early-stage Lung Cancer With Stereotactic Body Radiation Therapy or Sub-lobar Resection.
    Clin Lung Cancer. 2025 Aug 23:S1525-7304(25)00217.
    PubMed        
    
    

    
    Eur J Cardiothorac Surg

16. SHIH BC, Jung W, Lee JH, Cho S, et al
    Perineural invasion affects the risk and pattern of recurrence in non-small cell lung cancer.
    Eur J Cardiothorac Surg. 2025 Sep 19:ezaf299. doi: 10.1093.
    PubMed         Abstract available
    
    
17. AHMAD M, Saleh MA
    Caution in interpreting lobectomy superiority for centrally located stage i non-small cell lung cancer.
    Eur J Cardiothorac Surg. 2025 Sep 19:ezaf309. doi: 10.1093.
    PubMed        
    
    
18. RUSCA GIMENEZ M, Gonzalez-Rivas D, Gomez Tabales J, Bosinceanu ML, et al
    Uniportal Robotic-Assisted Sleeve Resection of the Left Main Bronchus and Secondary Carinal Reconstruction for Typical Carcinoid Tumour.
    Eur J Cardiothorac Surg. 2025;67:ezaf280.
    PubMed         Abstract available
    
    
19. HE H, Yu C, Yang Y, Maessen JG, et al
    Three-Dimensional Reconstruction and Virtual Simulation of Patient-Specific Anatomy for Procedural Planning in Thoracoscopic Segmentectomy: A Systematic Review and Meta-Analysis.
    Eur J Cardiothorac Surg. 2025;67:ezaf283.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

20. FRIEDES C, Yegya-Raman N, Iocolano M, Levin WP, et al
    Primary Tumor Failure after Definitive Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer: A Brief Report on the Implications for NRG LU-008.
    Int J Radiat Oncol Biol Phys. 2025 Sep 16:S0360-3016(25)06276.
    PubMed         Abstract available
    
    

    
    J Immunol

21. KEREMITCI D, Tuna O, Houdjedj A, Kazan H, et al
    Transcriptional states of lung cancer microenvironment reveal macrophage subtype dynamics linked to disease progression.
    J Immunol. 2025 Sep 16:vkaf253. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Lung Cancer

22. RAJARAM R, Huang Q, Johnson BH, Laxmanan B, et al
    Implications of primary tumor size on overall survival in patients with multifocal T3 non-small cell lung cancer.
    Lung Cancer. 2025;208:108746.
    PubMed         Abstract available
    
    
23. ZHANG R, Yan H, Tian F, Jiang Y, et al
    Prognostic implications of uncommon EGFR exon 19 deletion-insertion mutations in non-small cell lung cancer treated with third-generation EGFR-TKIs.
    Lung Cancer. 2025;208:108755.
    PubMed         Abstract available
    
    
24. IWAMA E, Sakai K, Harada T, Kanda S, et al
    Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations.
    Lung Cancer. 2025;208:108756.
    PubMed         Abstract available
    
    
25. TAKEMURA C, Yoshida T, Yoshida Y, Inaba Higashiyama R, et al
    Unveiling the molecular and clinical risk landscape of second primary lung cancer in resected non-small cell lung cancer.
    Lung Cancer. 2025;208:108750.
    PubMed         Abstract available
    
    
26. WANG J, Cao H, He N, Liu X, et al
    Evolving Trends in Surgically Managed Lung Cancer: A 16-Year Hospital-Based Epidemiological Analysis.
    Lung Cancer. 2025;208:108754.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

27. WANG W, Tian S, Ou Y, Yang J, et al
    FBXW5 Promotes Epithelial-Mesenchymal Transition in Lung Adenocarcinoma Through the KLF13/TROAP Signaling Pathway.
    Mol Carcinog. 2025;64:1638-1649.
    PubMed         Abstract available
    
    

    
    Oncogene

28. YANG M, Lu Y, Zheng J, Zhao X, et al
    PRICKLE3-USP9X interaction-mediated DVL2 deubiquitination promotes the progression of non-small cell lung cancer via canonical WNT pathway.
    Oncogene. 2025 Sep 19. doi: 10.1038/s41388-025-03580.
    PubMed         Abstract available
    
    

    
    Oncol Rep

29. ZHAO C, Xu Y, Zhang Y, Tan W, et al
    [Expression of Concern] Downregulation of miR?145 contributes to lung adenocarcinoma cell growth to form brain metastases.
    Oncol Rep. 2025;54:158.
    PubMed         Abstract available
    
    
30. ZHENG WW, Ding JX, Liang YX, Ye L, et al
    Hydroxypropyl?beta?cyclodextrin/thymoquinone inclusion complex inhibits non?small cell lung cancer progression through NF?kappaB?mediated ferroptosis.
    Oncol Rep. 2025;54:157.
    PubMed         Abstract available
    
    

    
    Oncologist

31. LIU Y, Liu F, Wang C, Yan Y, et al
    Clinicopathological and molecular characteristics and treatment outcomes of SMARCA4-deficient thoracic tumors: a comprehensive analysis.
    Oncologist. 2025;30:oyaf266.
    PubMed         Abstract available
    
    
32. LISBERG A, Huppert LA, Halmos B, Ledezma B, et al
    Datopotamab deruxtecan-associated select adverse events: clinical practices and institutional protocols on prophylaxis, monitoring, and management.
    Oncologist. 2025;30:oyaf225.
    PubMed         Abstract available
    
    

    
    PLoS One

33. KIZILTAN HS, Cepni K
    Prognostic value of D-dimer in treatment and follow up for patients who underwent radiotherapy in advanced lung cancer.
    PLoS One. 2025;20:e0333085.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.